相关实验视频

Updated: Jun 18, 2026

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

瓦尔帕尔夫®:一种含有牛乳酸的新型营养药物配方,表现出潜在的生物活性

Luigi Rosa¹, Giusi Ianiro², Antonella Niro²

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.

International journal of molecular sciences

|August 29, 2024

概括

作为一种新的牛乳酸 (bLf) 配方,Valpalf®显示出增强的铁结合和核积累. 这种配方有效降低炎症并增强抗氧化酶,在治疗炎症性贫血方面表现优于原生BLF.

科学领域:

生物化学生物化学
免疫学免疫学免疫学
营养学科学营养学科学

背景情况:

牛乳酸 (bLf) 是一种具有先天免疫功能的铁结合型糖蛋白.
bLf表现出与铁化和核进入相关的抗炎和抗氧化特性.
高耐受性和性功能使得bLf成为一个有前途的营养药.

研究的目的:

为了评估Valpalf®,一个新的bLf配方与酸和碳酸.
为了比较Valpalf®与本地BLf的生物活性.
在细胞模型和对炎症性贫血的临床研究中评估Valpalf®的疗效.

主要方法:

在体外评估铁结合能力,三性消化阻力和核积累.
在脂多糖刺激的巨细胞中对IL-6降低的评估.
在刺激的单细胞中调节抗氧化酶 (SOD1,SOD2).
关于遗传性血栓性女性炎症性贫血的回顾性临床研究.

主要成果:

与本地bLf相比,Valpalf®表现出优越的铁结合,耐消化性和核积累能力.
瓦尔帕尔夫显著降低了IL-6水平,并调节了抗氧化酶的表达.
该配方改善了血液学参数,并在临床环境中比单独使用BLf更有效地降低了IL-6.

结论:

由于其配方,Valpalf®表现出增强的生物活性.
该配方显示出作为一种有效的营养药物在炎症和贫血中具有潜力.
瓦尔帕尔夫 (Valpalf®) 代表了一种优越的替代品,用于治疗应用.

关键词:

瓦尔帕尔夫 (Valpalf®) 的使用方法炎症的贫血炎症的贫血它具有抗炎活性,具有抗炎活性.抗氧化剂活性抗氧化剂活性牛乳酪蛋白是牛乳酪蛋白中的一种.铁化铁化铁化蛋白质溶解的抗性.

更多相关视频

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids

Published on: May 4, 2018

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Published on: August 31, 2019

相关概念视频

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Pharmaceutical Equivalents

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Probiotics

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...